- Home
- RSF vs BEAT Comparison
RSF vs BEAT Comparison
Compare RSF & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSF
- BEAT
- Stock Information
- Founded
- RSF 2016
- BEAT 2015
- Country
- RSF United States
- BEAT United States
- Employees
- RSF N/A
- BEAT N/A
- Industry
- RSF Investment Managers
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- RSF Finance
- BEAT Technology
- Exchange
- RSF Nasdaq
- BEAT Nasdaq
- Market Cap
- RSF 63.1M
- BEAT 63.5M
- IPO Year
- RSF N/A
- BEAT 2021
- Fundamental
- Price
- RSF $14.49
- BEAT $1.56
- Analyst Decision
- RSF
- BEAT Buy
- Analyst Count
- RSF 0
- BEAT 1
- Target Price
- RSF N/A
- BEAT $8.00
- AVG Volume (30 Days)
- RSF 11.8K
- BEAT 86.1K
- Earning Date
- RSF 01-01-0001
- BEAT 11-13-2025
- Dividend Yield
- RSF 10.61%
- BEAT N/A
- EPS Growth
- RSF N/A
- BEAT N/A
- EPS
- RSF N/A
- BEAT N/A
- Revenue
- RSF N/A
- BEAT N/A
- Revenue This Year
- RSF N/A
- BEAT N/A
- Revenue Next Year
- RSF N/A
- BEAT $28.23
- P/E Ratio
- RSF N/A
- BEAT N/A
- Revenue Growth
- RSF N/A
- BEAT N/A
- 52 Week Low
- RSF $14.81
- BEAT $0.91
- 52 Week High
- RSF $16.23
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- RSF 31.87
- BEAT 44.23
- Support Level
- RSF $14.65
- BEAT $1.62
- Resistance Level
- RSF $14.89
- BEAT $1.74
- Average True Range (ATR)
- RSF 0.15
- BEAT 0.13
- MACD
- RSF -0.02
- BEAT -0.01
- Stochastic Oscillator
- RSF 17.05
- BEAT 30.88
About RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.